Skip to main content
COAG logo

COAG · Hemab Therapeutics Holdings, Inc. · Holdings

Track COAG — free
$39.33 +0.18 (+0.45%) Play latest call Q3 2026 earnings call transcript
Market Cap
$1.83B
Shares
46.73M
Volume · Nov 19 34.62K Avg daily vol (3M) 496.12K

Institutional ownership from SEC Form 13F filings. Investment managers with more than $100 million in U.S. equities must disclose their positions every quarter, within 45 days of quarter-end, so the holdings shown can lag the market by up to a quarter.

Holders: 89
Total Value: $1,229,453,512
Total Shares: 39,865,550

Institutional Ownership Trend

2 quarters

Holder Concentration

Share of 13F common-share value, across 89 filers with any position, options included · Δ vs Jun 30, 2026
Top Holder
19.6%
Jun 2026 → Sep 2026 · range 19.6% – 21.5%
−1.9 pts
Top 5
57.4%
Jun 2026 → Sep 2026 · range 57.4% – 63.1%
−5.7 pts
Top 10
78.1%
Jun 2026 → Sep 2026 · range 78.1% – 84.1%
−6.0 pts
HHI
864
Jun 2026 → Sep 2026 · range 864 – 1,013
Broadly held−149

Who Holds COAG

Last 2 quarters through Sep 30, 2026

Each kind of 13F filer's share of the common shares 13F filers report. Holder type comes from regulatory records, never the filer's name; style, turnover and horizon are measured from each filer's own 13F book. The quarter selector does not change this card.

Sep 30, 2026: 89 filers, like-for-like change +9.9%; actively managed books +2.9%; index-like books +155.4%.

Holder type Share Filers Change
Registered adviser 39.6% 37 +7.6%
Exempt adviser 0.0% 1 -88.9%
Adviser 18.2% 5 -0.5%
Bank 5.7% 10 +72.1%
Benefit plan 0.1% 2 new
Non-US 1.5% 5 +6.7%
Holding company 13.1% 4 +28.9%
Unknown 21.8% 25 +5.7%
How the mix is measured

Shares are 13F common shares restated to today's split basis; options and principal amounts are left out. The change compares only filers with a 13F in both quarters and keeps each filer in its bucket of the later quarter on both sides; a filer that continues under a new CIK is compared through its successor. Holder type comes from each filer's current regulatory profile; client base and private funds come from the Form ADV roster current at each quarter end (rosters from December 2019, so an earlier quarter reads Unknown). Style, turnover, horizon and book size are measured from each filer's 13F book in the newest measured quarter, and Not measured means none was. Actively managed books are those measured systematic-like, concentrated or diversified active.

Excluded 1 holder with no observed 2026-06-30 13F.

Conviction and Crowding

89 13F filers, quarter ended Sep 30, 2026

Measured across every 13F filer's common-share book once the quarter's filing window closed. Crowding counts filers with high turnover or that advise private funds on Form ADV.

Conviction holders
2
2.25% of filers hold it in their top 10
Jun 30, 2026: 3
Holders above 5%
1
median weight 0.001%
Jun 30, 2026: 1
Crowding
30.6%
of shares outstanding, 80th percentile
Jun 30, 2026: 29.4%
Private-fund advisers
30.3%
of shares outstanding
Institutional ownership
85.3%
95.6% of the estimated free float
Top 10 holders
78.1%
of 13F shares, Herfindahl 0.086
Active holders
+2.9%
like-for-like share change of active filers
5% stakes on record
9
1 13D, 8 13G (3 institutional, 3 passive, 2 exempt)
How long holders have held it value-weighted 2.0 quarters
Under 1 year 100.0% 1 to 3 years 0.000% 3 years or more 0.000% Since coverage start 0.000%

Managers in the top fifth by current three-year FundScore alpha were net buyers of $31,180,180 (7 buying, 6 selling).

Estimated Holder Cost Basis

Quarter ended Sep 30, 2026, on that quarter's share basis

Estimated, never filed: each 13F buy is costed at its quarter's average traded price and each sale keeps the average cost, so this is what holders paid on average if they traded evenly through each quarter.

Estimated avg cost
$29.66
estimated per share
Jun 30, 2026: $27.59
Quarter-end price
$30.84
implied by 13F values
Estimated gain or loss
+4.0%
price against the estimated cost
Estimated at a loss
14.5%
of costed 13F value

Estimated cost covers 100.0% of the 13F shares; positions already held when a filer's 13F history starts, or bought in a quarter without a trusted average price, have no estimate.

Shared Holders

Companies COAG's active holders also own, quarter ended Sep 30, 2026
# Company Shared holders
1 XENE Xenon Pharmaceuticals Inc. 9
2 BCAX Bicara Therapeutics Inc. 5
3 GPCR Structure Therapeutics Inc. 7
4 IRON Disc Medicine, Inc. 7
5 SLDB Solid Biosciences Inc. 5
6 TYRA Tyra Biosciences, Inc. 5
7 VRDN Viridian Therapeutics, Inc.DE 7
8 FDMT 4D Molecular Therapeutics, Inc. 5
9 GHRS GH Research PLC 4
10 ENTX Entera Bio Ltd. 5

Shareholder Targets

13F filers that own its peers but not COAG, quarter ended Sep 30, 2026

Found through its holder-overlap peers: XENE, BCAX, GPCR, IRON, SLDB, TYRA, VRDN, FDMT, GHRS, ENTX, MBX, OLMA, PBLS, AVLN, MLYS, DMRA, ORKA, TNGX, PCVX, CLYM. 688 filers in all.

# Filer In peers
1 T. Rowe Price Investment Management, Inc. Adviser, Diversified active $1,608,069,150 7 held
2 WELLINGTON MANAGEMENT GROUP LLP Holding company, Diversified active $1,371,977,386 14 held
3 RTW INVESTMENTS, LP Registered adviser, Diversified active $968,407,263 7 held
4 Fairmount Funds Management LLC Registered adviser, Concentrated $598,846,118 3 held
5 Polar Capital Holdings Plc Registered adviser, Diversified active $541,249,611 6 held
6 BVF INC/IL Unknown, Concentrated $531,322,902 7 held
7 Frazier Life Sciences Management, L.P. Registered adviser, Concentrated $526,396,330 3 held
8 Venrock Adviser, LLC Registered adviser, Concentrated $524,328,270 5 held
9 FRANKLIN RESOURCES INC Adviser, Diversified active $518,811,113 13 held
10 TCG Crossover Management, LLC Unknown, Diversified active $406,610,151 5 held

Fund Ownership of COAG by Fund Type

Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026

Index funds and index ETFs hold 1.70% of shares outstanding.

Fund type Of shares outstanding Shares
Index funds 0.06% 28,857
Index ETFs 1.64% 767,263
Active ETFs 0.07% 32,484
Active funds 14.62% 6,832,518
Unclassified 0.24% 112,414
All registered funds 16.63% 7,773,536
How fund types are measured

Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.

Quarterly Activity

vs Jun 30, 2026
New
41
Increased
24
Decreased
12
Sold Out
9
Unchanged
11

New and Sold Out count only filers that reported a 13F for both quarters: a first-time filer's book is not a buy, and a fund that has not filed, or withheld its positions under confidential treatment, has not sold.

Holder count: +33
Institutional value: -7.7%
Shares held: +9.9%

Top Buyers

vs Jun 30, 2026
Institution Added Now Holds Open

Top Sellers

vs Jun 30, 2026
Institution Sold Now Holds Open

Top New Positions

vs Jun 30, 2026
Institution Acquired Value (USD) Open

Top Sold-Out Positions

vs Jun 30, 2026
Institution Previously Held Last Value (USD) Open
Showing 89 of 89
Export CSV
Holder Value (USD) % of 13F Shares Own % Change Type Filed Open
Key facts CIK 2114044 CUSIP 423494103 13F (30d) 89 filings 88 filers Visit website Investor relations